Substudy 1

Sponsor:
Day One Biopharmaceuticals, Inc.

Status:
Currently enrolling patients

Condition:
Solid tumors with known activating BRAF fusions or CRAF/RAF1 fusions or amplifications

Intervention:
DAY101 monotherapy

Phase:
2

NCT Number:
NCT04985604

Substudy 2

Sponsor:
Day One Biopharmaceuticals, Inc.

Status:
Currently enrolling patients

Condition:
Solid tumors with MAPK pathway alterations

Intervention:
DAY101 in combination with Pimasertib, an investigational MEK1 and MEK2 inhibitor

Phase:
1b/2

NCT Number:
NCT04985604

Interested in learning more?
Click here to contact a member of the Day One Clinical team